Are you Dr. Parsley?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6400 Fannin St
2280
Houston, TX 77030Phone+1 713-795-5155Fax+1 713-795-5515
Summary
- Dr. Edwin Parsley, DO is an internist in Houston, Texas. He is currently licensed to practice medicine in Texas, California, and Oklahoma.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Pulmonary Disease and Critical Care Medicine, 1993 - 1996
Oklahoma State University Center for Health SciencesClass of 1988
Certifications & Licensure
CA State License 2016 - 2025
OK State License 1984 - 2023
TX State License 1992 - 2018
Clinical Trials
- Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer Start of enrollment: 2016 Jan 01
Publications & Presentations
PubMed
- 1048 citationsCyclophosphamide versus placebo in scleroderma lung disease.Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan G. Goldin, Michael D. Roth
The New England Journal of Medicine. 2006-06-22 - 295 citationsEffects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Michael D. Roth, Daniel E. Furst
American Journal of Respiratory and Critical Care Medicine. 2007-11-15 - 70 citationsImpact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.Dinesh Khanna, Xiaohong Yan, Donald P. Tashkin, Daniel E. Furst, Robert Elashoff
Arthritis and Rheumatism. 2007-05-01
Press Mentions
Mast Therapeutics Initiates Phase 2 Study of Vepoloxamer for the Treatment of Chronic Heart FailureOctober 26th, 2015
Professional Memberships
- Member
